MedTrace Logo

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

NCT01451164 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 459

Last updated 2019-10-03

Study results available
· View outcomes & findings →

Summary

To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.

Conditions

Interventions

DRUG

OPC-34712

orally administered once daily

DRUG

OPC-34712

orally administered once daily

DRUG

OPC-34712

orally administered once daily

DRUG

Placebo

orally administered once daily

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • kyoji Imaoka, Operating Officer · Otsuka Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2015-06-30

Countries

  • Japan

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01451164 on ClinicalTrials.gov